Novo Nordisk's shrinking dominance tests its future in diabetes and obesity drugs

Novo Nordisk remains a key player in the diabetes and weight-loss drug market, despite facing stronger competition from rivals like Eli Lilly. The company's shares have underperformed the broader stock market in recent years, even as its GLP-1 therapies like semaglutide continue to dominate sales. Analysts still see long-term potential, but challenges from competitors are growing.

Over the past three years, Novo Nordisk's grip on the GLP-1 market has weakened. From 2023 to 2025, its global share dropped from around 55% to 45%, while Eli Lilly's share climbed from 35% to 50%. Lilly's drugs, Mounjaro and Zepbound, have outperformed Novo's Ozempic and Wegovy in U.S. sales and new prescriptions, according to IQVIA data. Revenue for Novo Nordisk is now expected to dip in 2026 as competition intensifies in the stock market.

The company still holds strengths, including a deep pipeline of new treatments and a strong cash position for licensing deals or acquisitions. Several of its experimental GLP-1 drugs are nearing approval, which could help offset losses. Yet, even with near-perfect execution, analysts doubt Novo Nordisk can sustain a 25.89% annual growth rate over the next decade in the stock market.

Novo Nordisk continues to lead in diabetes care and is expanding into other areas. Its dividend potential and long-term market position may appeal to investors, but the rise of Eli Lilly and other competitors limits its upside in the stock market.

Novo Nordisk's future hinges on balancing its established leadership in diabetes with the pressure from rivals in the stock market. While its pipeline and financial strength provide advantages, the company's declining market share signals tougher battles ahead. Investors will watch closely as new drugs enter the market and competition reshapes the industry in the stock market.